Latest Deals

Credit: Kmpzzz / Shutterstock.

Avation Medical has raised more than $22m in Series C financing to fund the US launch of its Vivally system for patients suffering from urge urinary incontinence and urinary urgency caused by overactive bladder syndrome (OAB). The wearable device is a non-invasive neuromodulation system that targets the tibial nerve and delivers closed-loop, autonomously adjusted electrical stimulation. The device received 510(k) clearance from the US Food and Drug Administration (FDA) in April 2023. 

Synergy Spine Solutions has closed a Series A funding round worth $30m, which will be used to advance its artificial cervical disc Synergy Disc through clinical trials and regulatory clearings. The funding, spearheaded by Amzak Health alongside other investors, is earmarked for key initiatives such as the completion of enrolment in the IDE 2-level clinical trial, and patient follow-up on both the 1-level (NCT04469231) and 2-level (NCT05740176) clinical trials. Amzak completed enrolment for the 1-level trial in June 2023. 

Aditxt has acquired a suite of electroencephalography (EEG) brain monitoring technologies and devices which were previously owned by Brain Scientific. The portfolio of assets includes 16 patents, with the NeuroCap and NeuroEEG as flagship products, designed to improve EEG test efficiency and patient comfort. The acquisition will bolster the capabilities of Aditxt’s subsidiary Pearsanta, allowing it to offer advanced neurological diagnostics and monitoring solutions. 

Paris-based biotech Aqemia has secured €30m ($32.5m) in Series A funding to advance its generative artificial intelligence (AI)-led drug pipeline. The company previously raised €30m in October 2022, bringing the total Series A round to €60m. Paris-based investment company Wendel Growth led the round.